Survival following allogeneic transplant in patients with myelofibrosis
Name:
advancesadv2019001084.pdf
Size:
854.5Kb
Format:
PDF
Description:
Final Published Version
Author
Gowin, KrisstinaBallen, Karen
Ahn, Kwang Woo
Hu, Zhen-Huan
Ali, Haris
Arcasoy, Murat O
Devlin, Rebecca
Coakley, Maria
Gerds, Aaron T
Green, Michael
Gupta, Vikas
Hobbs, Gabriela
Jain, Tania
Kandarpa, Malathi
Komrokji, Rami
Kuykendall, Andrew T
Luber, Kierstin
Masarova, Lucia
Michaelis, Laura C
Patches, Sarah
Pariser, Ashley C
Rampal, Raajit
Stein, Brady
Talpaz, Moshe
Verstovsek, Srdan
Wadleigh, Martha
Agrawal, Vaibhav
Aljurf, Mahmoud
Angel Diaz, Miguel
Avalos, Belinda R
Bacher, Ulrike
Bashey, Asad
Beitinjaneh, Amer M
Cerny, Jan
Chhabra, Saurabh
Copelan, Edward
Cutler, Corey S
DeFilipp, Zachariah
Gadalla, Shahinaz M
Ganguly, Siddhartha
Grunwald, Michael R
Hashmi, Shahrukh K
Kharfan-Dabaja, Mohamed A
Kindwall-Keller, Tamila
Kröger, Nicolaus
Lazarus, Hillard M
Liesveld, Jane L
Litzow, Mark R
Marks, David I
Nathan, Sunita
Nishihori, Taiga
Olsson, Richard F
Pawarode, Attaphol
Rowe, Jacob M
Savani, Bipin N
Savoie, Mary Lynn
Seo, Sachiko
Solh, Melhem
Tamari, Roni
Verdonck, Leo F
Yared, Jean A
Alyea, Edwin
Popat, Uday
Sobecks, Ronald
Scott, Bart L
Nakamura, Ryotaro
Mesa, Ruben
Saber, Wael
Affiliation
Univ Arizona, Div Hematol & OncolIssue Date
2020-05-08
Metadata
Show full item recordPublisher
AMER SOC HEMATOLOGYCitation
Gowin, K., Ballen, K., Ahn, K. W., Hu, Z. H., Ali, H., Arcasoy, M. O., ... & Saber, W. (2020). Survival following allogeneic transplant in patients with myelofibrosis. Blood advances, 4(9), 1965-1973.Journal
BLOOD ADVANCESRights
© 2020 by The American Society of Hematology.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF patients treated with allogeneic HCT (551 patients) and without HCT (non-HCT) (1377 patients) was analyzed with Cox proportional hazards model. Survival analysis stratified by the Dynamic International Prognostic Scoring System (DIPSS) revealed that the first year of treatment arm assignment, due to upfront risk of transplant-related mortality (TRM), HCT was associated with inferior OS compared with non-HCT (non-HCT vs HCT: DIPSS intermediate 1 [Int-1]: hazard ratio [HR] = 0.26, P < .0001; DIPSS-Int-2 and higher: HR, 0.39, P < .0001). Similarly, in the DIPSS low-risk MF group, due to upfront TRM risk, OS was superior with non-HCT therapies compared with HCT in the first-year post treatment arm assignment (HR, 0.16, P = .006). However, after 1 year, OS was not significantly different (HR, 1.38, P = .451). Beyond 1 year of treatment arm assignment, an OS advantage with HCT therapy in Int-1 and higher DIPSS score patients was observed (non-HCT vs HCT: DIPSS-Int-1: HR, 2.64, P < .0001; DIPSS-Int-2 and higher: HR, 2.55, P < .0001). In conclusion, long-term OS advantage with HCT was observed for patients with Int-1 or higher risk MF, but at the cost of early TRM. The magnitude of OS benefit with HCT increased as DIPSS risk score increased and became apparent with longer follow-up.ISSN
2473-9529EISSN
2473-9537PubMed ID
32384540Version
Final published versionae974a485f413a2113503eed53cd6c53
10.1182/bloodadvances.2019001084
Scopus Count
Collections
Related articles
- Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes.
- Authors: Samuelson Bannow BT, Salit RB, Storer BE, Stevens EA, Wu D, Yeung C, Fang M, Petersdorf EW, Linenberger ML, Woo J, Sorror ML, Doney K, Sandmaier BM, Deeg HJ, Scott BL
- Issue date: 2018 Feb
- Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis-A Systematic Review and Meta-Analysis.
- Authors: Bewersdorf JP, Sheth AH, Vetsa S, Grimshaw A, Giri S, Podoltsev NA, Gowda L, Tamari R, Tallman MS, Rampal RK, Zeidan AM, Stahl M
- Issue date: 2021 Oct
- Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.
- Authors: Maze D, Arcasoy MO, Henrie R, Cerquozzi S, Kamble R, Al-Hadidi S, Yacoub A, Singh AK, Elsawy M, Sirhan S, Smith E, Marcoux C, Viswabandya A, Daly A, Sibai H, McNamara C, Shi Y, Xu W, Lajkosz K, Foltz L, Gupta V
- Issue date: 2024 Feb
- Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation.
- Authors: Acosta-Medina AA, Baranwal A, Johnson IM, Kharfan-Dabaja MA, Murthy H, Palmer JM, Sproat L, Mangaonkar A, Shah MV, Hogan WJ, Litzow MR, Tefferi A, Alkhateeb HB
- Issue date: 2023 Jun
- Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients.
- Authors: Kuykendall AT, Talati C, Padron E, Sweet K, Sallman D, List AF, Lancet JE, Komrokji RS
- Issue date: 2019 Jan